As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How is the field adapting to meet these new demands?
6dOpinion
A message from the SEC's Uyeda: If you don't like SpaceX's governance, don't buy the shares
The tight control kept by CEO Elon Musk and a rush by index providers to add the shares cut across corporate-governance norms ...
Nordot on MSN
Beyond the digital screen: Pixar’s Sonoko Konishi on crafting the soul of "Toy Story 5"
Story by TK Ogawa It’s been nearly 30 years since the original "Toy Story" screened in Japan back in 1996. Since then, Disney ...
Flagships, foldables, midrangers and affordable models - there are plenty of desirable upcoming phones on the way ...
The 800 V DC transition is inevitable but fraught, as hyperscalers race ahead while safety standards and ecosystem readiness lag behind. During PCIM Europe 2026, Power Electronics News had the ...
Here, Vidya Vijay, Director of Business Development at Nordson Test and Inspection, examines how intelligent in-situ sensing ...
Using AI and Australia's supercomputing infrastructure, researchers mapped 94 million craters on Mars, transforming planetary ...
A major transition in evolution is the shift from asexual to sexual reproduction in early organisms. But why would a yeast ...
Apple has unveiled iOS 27 Beta 3, a significant update that combines visual refinements , feature enhancements , and ...
Evolutionary psychology is known for dark parts of our nature, like homicide. But it also explains prosocial behaviors, like ...
By registering the LongCat-2.0 repository under the open-source MIT License, Meituan positions the architecture with maximum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results